JP2023501940A - ラグタイム減少/アイススプレー - Google Patents
ラグタイム減少/アイススプレー Download PDFInfo
- Publication number
- JP2023501940A JP2023501940A JP2022525250A JP2022525250A JP2023501940A JP 2023501940 A JP2023501940 A JP 2023501940A JP 2022525250 A JP2022525250 A JP 2022525250A JP 2022525250 A JP2022525250 A JP 2022525250A JP 2023501940 A JP2023501940 A JP 2023501940A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- cold spray
- skin
- dosage form
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 45
- 239000004480 active ingredient Substances 0.000 claims abstract description 55
- 239000002552 dosage form Substances 0.000 claims abstract description 32
- 238000010521 absorption reaction Methods 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 239000002674 ointment Substances 0.000 claims description 14
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000001961 anticonvulsive agent Substances 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 229940124810 Alzheimer's drug Drugs 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- 229940035674 anesthetics Drugs 0.000 claims description 4
- 230000000954 anitussive effect Effects 0.000 claims description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 4
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 4
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 230000003556 anti-epileptic effect Effects 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 4
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 229940124584 antitussives Drugs 0.000 claims description 4
- 239000001273 butane Substances 0.000 claims description 4
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229960003750 ethyl chloride Drugs 0.000 claims description 4
- 239000003172 expectorant agent Substances 0.000 claims description 4
- 230000003419 expectorant effect Effects 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 4
- 230000000147 hypnotic effect Effects 0.000 claims description 4
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000842 neuromuscular blocking agent Substances 0.000 claims description 4
- 239000001294 propane Substances 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 230000001624 sedative effect Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229940036555 thyroid hormone Drugs 0.000 claims description 4
- 239000005495 thyroid hormone Substances 0.000 claims description 4
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229940125708 antidiabetic agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 239000000939 antiparkinson agent Substances 0.000 claims description 3
- 239000003434 antitussive agent Substances 0.000 claims description 3
- 230000003177 cardiotonic effect Effects 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 229940066493 expectorants Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 32
- 239000011159 matrix material Substances 0.000 description 7
- 230000008591 skin barrier function Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000036572 transepidermal water loss Effects 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 4
- 229960001736 buprenorphine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940020452 neupro Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229940035678 anti-parkinson drug Drugs 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- -1 antihypertensive Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000013039 cover film Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
・患者の皮膚の少なくとも1つの領域を冷却するステップと
・少なくとも1つの薬学的活性成分を経皮投与するための剤形を、皮膚の冷却された領域に適用するステップと
を含む、患者を処置する方法に関する。
Claims (15)
- 少なくとも1つのコールドスプレーと、少なくとも1つの薬学的活性成分を経皮投与するための少なくとも1つの剤形とを含む、キット。
- 少なくとも1つの剤形が、経皮治療システム、ゲル、ローション、軟膏、クリームおよび/またはマイクロニードルシステムを含むことを特徴とする、請求項1に記載のキット。
- 少なくとも1つの薬学的活性成分が、催眠薬、鎮静薬、抗てんかん薬、興奮薬、向精神神経薬、神経筋遮断薬、鎮痙薬、抗ヒスタミン薬、抗アレルギー薬、強心薬、抗不整脈薬、利尿薬、降圧薬、血管収縮薬、鎮咳薬、去痰薬、鎮痛薬、甲状腺ホルモン、性ホルモン、グルココルチコイドホルモン、抗糖尿病薬、抗腫瘍薬、抗生物質、化学療法薬、麻酔薬、抗パーキンソン薬、抗アルツハイマー薬および/またはトリプタンからなる群から選ばれることを特徴とする、請求項1または2に記載のキット。
- コールドスプレーが、スプレー缶に充填された液体ガスを含むことを特徴とする、請求項1~3のいずれか1項に記載のキット。
- 液体ガスが、プロパン、ブタン、ペンタン、テトラフルオロエタン、ジメチルエーテルおよび/またはクロロエタンを含むことを特徴とする、請求項4に記載のキット。
- 患者の処置に使用するための請求項1~5のいずれか1項に記載のキット。
- 少なくとも1つの薬学的活性成分を経皮投与するための剤形の適用において、吸収遅延時間を低減するためのコールドスプレーの使用。
- 剤形が、経皮治療システム、ゲル、ローション、懸濁性軟膏および/またはマイクロニードルシステムを含むことを特徴とする、請求項7に記載の使用。
- 少なくとも1つの薬学的活性成分が、催眠薬、鎮静薬、抗てんかん薬、興奮薬、向精神神経薬、神経筋遮断薬、鎮痙薬、抗ヒスタミン薬、抗アレルギー薬、強心薬、抗不整脈薬、利尿薬、降圧薬、血管収縮薬、鎮咳薬、去痰薬、鎮痛薬、甲状腺ホルモン、性ホルモン、グルココルチコイドホルモン、抗糖尿病薬、抗腫瘍薬、抗生物質、化学療法薬、麻酔薬、抗パーキンソン薬、抗アルツハイマー薬および/またはトリプタンからなる群から選ばれることを特徴とする、請求項7または8に記載の使用。
- コールドスプレーが、スプレー缶に充填された液体ガスを含むことを特徴とする、請求項7~9のいずれか1項に記載の使用。
- 液体ガスが、プロパン、ブタン、ペンタン、テトラフルオロエタン、ジメチルエーテルおよび/またはクロロエタンを含むことを特徴とする、請求項10に記載の使用。
- 患者を処置する方法であって、以下のステップ:
・患者の皮膚の少なくとも1つの領域を冷却するステップと、
・少なくとも1つの薬学的活性成分を経皮投与するための剤形を、皮膚の冷却された領域に適用するステップと
を含む、方法。 - 皮膚がコールドスプレーで処置されることによって冷却されることを特徴とする、請求項12に記載の方法。
- コールドスプレーによる処置が、3秒から20秒の間続くことを特徴とする、請求項13に記載の方法。
- 剤形が、経皮治療システム、ゲル、ローション、懸濁性軟膏および/またはマイクロニードルシステムを含むことを特徴とする、請求項12~14のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019129444.4A DE102019129444A1 (de) | 2019-10-31 | 2019-10-31 | Lagtime-Verkürzung/Eisspray |
DE102019129444.4 | 2019-10-31 | ||
PCT/EP2020/077108 WO2021083593A1 (de) | 2019-10-31 | 2020-09-28 | Lagtime-verkürzung/eisspray |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023501940A true JP2023501940A (ja) | 2023-01-20 |
Family
ID=72670728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022525250A Pending JP2023501940A (ja) | 2019-10-31 | 2020-09-28 | ラグタイム減少/アイススプレー |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220409533A1 (ja) |
EP (1) | EP4009947B1 (ja) |
JP (1) | JP2023501940A (ja) |
CN (1) | CN114502143A (ja) |
BR (1) | BR112022003348A2 (ja) |
CA (1) | CA3154122A1 (ja) |
DE (1) | DE102019129444A1 (ja) |
WO (1) | WO2021083593A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10000085A1 (de) * | 2000-01-04 | 2001-07-05 | Pierre Nicolas Foss | Emla-Creme-Verbesserung |
DE102011112374A1 (de) * | 2011-09-02 | 2013-03-07 | Dr. Theiss Naturwaren Gmbh | Verfahren zur Straffung der menschlichen Haut und Mittel zur Durchführung dieses Verfahrens |
EP2910276A1 (en) * | 2014-02-21 | 2015-08-26 | Sharon Hilditch | Skin treatment device |
JP2017522995A (ja) * | 2014-08-04 | 2017-08-17 | ソフト メディカル アスセティクス | 患者の皮膚の下へ鈍端カニューレを挿入するためのデバイス |
JP2018503644A (ja) * | 2015-01-16 | 2018-02-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リキシセナチドを用いた小児2型真性糖尿病患者の治療 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69631170T2 (de) | 1995-05-04 | 2004-08-05 | Opusdent Ltd. | Lasersystem |
DE10230558B4 (de) * | 2002-07-05 | 2007-08-02 | Lts Lohmann Therapie-Systeme Ag | Medizinisches Set zur Verabreichung in einer Kombinationstherapie |
US7183057B2 (en) | 2004-03-31 | 2007-02-27 | Dermtech International | Tape stripping methods for analysis of skin disease and pathological skin state |
US11395908B2 (en) * | 2015-01-23 | 2022-07-26 | Brain Tunnelgenix Technologies Corp. | Apparatus and method for skin treatment |
CA2982803C (en) | 2015-04-07 | 2023-02-28 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for delivering liquid formulations |
CN106727693A (zh) * | 2017-01-05 | 2017-05-31 | 成都平医药科技发展有限公司 | 一种抗菌消炎镇痛喷雾剂及其制备方法与应用 |
US20190060220A1 (en) * | 2017-08-29 | 2019-02-28 | Richard Postrel | Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management |
CA3085633A1 (en) | 2017-12-14 | 2019-06-20 | Lts Lohmann Therapie-Systeme Ag | Microneedle array comprising an active ingredient in the form of salts |
-
2019
- 2019-10-31 DE DE102019129444.4A patent/DE102019129444A1/de active Pending
-
2020
- 2020-09-28 CN CN202080066702.3A patent/CN114502143A/zh active Pending
- 2020-09-28 EP EP20781504.4A patent/EP4009947B1/de active Active
- 2020-09-28 US US17/773,383 patent/US20220409533A1/en active Pending
- 2020-09-28 CA CA3154122A patent/CA3154122A1/en active Pending
- 2020-09-28 JP JP2022525250A patent/JP2023501940A/ja active Pending
- 2020-09-28 BR BR112022003348A patent/BR112022003348A2/pt unknown
- 2020-09-28 WO PCT/EP2020/077108 patent/WO2021083593A1/de active Search and Examination
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10000085A1 (de) * | 2000-01-04 | 2001-07-05 | Pierre Nicolas Foss | Emla-Creme-Verbesserung |
DE102011112374A1 (de) * | 2011-09-02 | 2013-03-07 | Dr. Theiss Naturwaren Gmbh | Verfahren zur Straffung der menschlichen Haut und Mittel zur Durchführung dieses Verfahrens |
EP2910276A1 (en) * | 2014-02-21 | 2015-08-26 | Sharon Hilditch | Skin treatment device |
JP2017522995A (ja) * | 2014-08-04 | 2017-08-17 | ソフト メディカル アスセティクス | 患者の皮膚の下へ鈍端カニューレを挿入するためのデバイス |
JP2018503644A (ja) * | 2015-01-16 | 2018-02-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リキシセナチドを用いた小児2型真性糖尿病患者の治療 |
Also Published As
Publication number | Publication date |
---|---|
DE102019129444A1 (de) | 2021-05-06 |
EP4009947B1 (de) | 2024-06-26 |
WO2021083593A1 (de) | 2021-05-06 |
CA3154122A1 (en) | 2021-05-06 |
US20220409533A1 (en) | 2022-12-29 |
EP4009947A1 (de) | 2022-06-15 |
BR112022003348A2 (pt) | 2022-05-17 |
CN114502143A (zh) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tanaji | Emulgel: A comprehensive review for topical delivery of hydrophobic drugs | |
JP2547726B2 (ja) | フェンタニルの皮膚投与およびそのための装置 | |
KR102127344B1 (ko) | 피부 또는 점막에 활성 물질의 특정 용량을 투여하기 위한 전기수력학적으로 수득된 섬유를 포함하는 조성물 | |
JP5850889B2 (ja) | 薬物の皮膚送達のための接着性外皮形成製剤とそれを使用する方法 | |
US20140314815A1 (en) | Adhesive solid gel-forming formulations for dermal drug delivery | |
CN114206312A (zh) | 用于治疗炎性皮肤病的局部组合物和方法 | |
EP2872177B1 (en) | Diclofenac formulations | |
JP2015526480A (ja) | 治療剤の経皮送達を増強するための化学組成物および方法 | |
JP2002512600A (ja) | 経皮治療製剤 | |
PT1962817E (pt) | Administração transdérmica de uma forma de sal de meptazinol | |
KR20070008690A (ko) | 항콜린제를 위한 침투 강화 조성물 | |
JP2003525641A (ja) | 爪真菌症の治療用感圧接着性マトリックス・パッチ | |
Alam et al. | Type, preparation and evaluation of transdermal patch: a review | |
Stanekzai et al. | Recent approaches in transdermal drug delivery system | |
WO2005072775A1 (ja) | 消炎鎮痛外用剤 | |
AU2019349935B2 (en) | Transdermal drug delivery system | |
US6238693B1 (en) | Transdermal administration of fenoldopam | |
Reddy et al. | Transdermal drug delivery system: a review | |
JP2023501940A (ja) | ラグタイム減少/アイススプレー | |
JP2024507011A (ja) | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および/または処置におけるその使用 | |
JP2023546646A (ja) | 粘膜の穿孔 | |
CN110115710B (zh) | 一种用于治疗哮喘的透皮吸收制剂 | |
Banu et al. | Approaches and Current Trends of Transdermal Drug Delivery System-A Review | |
JPH1180031A (ja) | 外用剤及び経皮又は経粘膜吸収性を増進する方法 | |
Reddy et al. | Transdermal drug delivery system: a review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231102 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240206 |